Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
35,558,020
-
Share change
-
+1,040,303
-
Total reported value
-
$1,177,699,310
-
Put/Call ratio
-
114%
-
Price per share
-
$33.44
-
Number of holders
-
126
-
Value change
-
+$48,015,537
-
Number of buys
-
67
-
Number of sells
-
58
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2021
As of 30 Jun 2021 Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) had 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 35,558,020 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, Redmile Group, LLC, BlackRock Inc., EVENTIDE ASSET MANAGEMENT, LLC, STATE STREET CORP, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, ADAGE CAPITAL PARTNERS GP, L.L.C., VR Adviser, LLC, and ACUTA CAPITAL PARTNERS, LLC.
This table shows 127 institutional shareholders of the security as of 30 Jun 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.